Ikena Oncology, Inc.

NasdaqGM IKNA

Ikena Oncology, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -49.60

Ikena Oncology, Inc. Interest Coverage Ratio is -49.60 for the Trailing 12 Months (TTM) ending September 30, 2024, a 36.24% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Ikena Oncology, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -77.80, a -79.50% change year over year.
Ikena Oncology, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -43.34.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGM: IKNA

Ikena Oncology, Inc.

CEO	Dr. Mark Manfredi Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	645 Summer Street
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years